Compare EIG & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | HELP |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.6M | 889.9M |
| IPO Year | 2006 | 2020 |
| Metric | EIG | HELP |
|---|---|---|
| Price | $48.93 | $12.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 104.5K | ★ 1.6M |
| Earning Date | 04-29-2026 | 07-01-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | $23.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $3.76 |
| 52 Week High | $52.59 | $14.35 |
| Indicator | EIG | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 52.58 |
| Support Level | $48.30 | $11.26 |
| Resistance Level | $50.20 | $14.35 |
| Average True Range (ATR) | 0.94 | 1.04 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 40.15 | 33.76 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.